Nimish R Valvi
Overview
Explore the profile of Nimish R Valvi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1388
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dalton A, Weber Z, Allen K, Stenehjem E, Irving S, Spark T, et al.
Clin Infect Dis
. 2023 Jan;
76(9):1615-1625.
PMID: 36611252
Background: Coronavirus disease 2019 (COVID-19) vaccination coverage remains lower in communities with higher social vulnerability. Factors such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure risk and access to...
12.
Allen K, Hinrichs R, Heumann C, Titus M, Duszynski T, Valvi N, et al.
Sex Transm Dis
. 2022 Dec;
50(4):209-214.
PMID: 36584164
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are the 2 most common reported sexually transmitted infections in the United States. Current recommendations are to presumptively treat CT and/or GC in...
13.
DeSilva M, Mitchell P, Klein N, Dixon B, Tenforde M, Thompson M, et al.
J Infect Dis
. 2022 Nov;
227(8):961-969.
PMID: 36415904
Background: We assessed coronavirus disease 2019 (COVID-19) vaccination impact on illness severity among adults hospitalized with COVID-19, August 2021-March 2022. Methods: We evaluated differences in intensive care unit (ICU) admission,...
14.
Britton A, Embi P, Levy M, Gaglani M, DeSilva M, Dixon B, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Oct;
71(42):1335-1342.
PMID: 36264840
Persons with moderate-to-severe immunocompromising conditions might have reduced protection after COVID-19 vaccination, compared with persons without immunocompromising conditions (1-3). On August 13, 2021, the Advisory Committee on Immunization Practices (ACIP)...
15.
Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S, et al.
BMJ
. 2022 Oct;
379:e072141.
PMID: 36191948
Objective: To estimate the effectiveness of mRNA vaccines against moderate and severe covid-19 in adults by time since second, third, or fourth doses, and by age and immunocompromised status. Design:...
16.
Schrag S, Verani J, Dixon B, Page J, Butterfield K, Gaglani M, et al.
JAMA Netw Open
. 2022 Sep;
5(9):e2233273.
PMID: 36156146
Importance: Pregnant people are at high risk for severe COVID-19 but were excluded from mRNA vaccine trials; data on COVID-19 vaccine effectiveness (VE) are needed. Objective: To evaluate the estimated...
17.
Link-Gelles R, Levy M, Gaglani M, Irving S, Stockwell M, Dascomb K, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Jul;
71(29):931-939.
PMID: 35862287
The Omicron variant (B.1.1.529) of SARS-CoV-2, the virus that causes COVID-19, was first identified in the United States in November 2021, with the BA.1 sublineage (including BA.1.1) causing the largest...
18.
Natarajan K, Prasad N, Dascomb K, Irving S, Yang D, Gaglani M, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Mar;
71(13):495-502.
PMID: 35358170
CDC recommends that all persons aged ≥18 years receive a single COVID-19 vaccine booster dose ≥2 months after receipt of an Ad.26.COV2.S (Janssen [Johnson & Johnson]) adenovirus vector-based primary series...
19.
Klein N, Stockwell M, Demarco M, Gaglani M, Kharbanda A, Irving S, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Mar;
71(9):352-358.
PMID: 35239634
The efficacy of the BNT162b2 (Pfizer-BioNTech) vaccine against laboratory-confirmed COVID-19 exceeded 90% in clinical trials that included children and adolescents aged 5-11, 12-15, and 16-17 years (1-3). Limited real-world data...
20.
Ferdinands J, Rao S, Dixon B, Mitchell P, DeSilva M, Irving S, et al.
MMWR Morb Mortal Wkly Rep
. 2022 Feb;
71(7):255-263.
PMID: 35176007
CDC recommends that all persons aged ≥12 years receive a booster dose of COVID-19 mRNA vaccine ≥5 months after completion of a primary mRNA vaccination series and that immunocompromised persons...